These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 26244163)

  • 1. Targeting CD44 as a novel therapeutic approach for treating pancreatic cancer recurrence.
    Molejon MI; Tellechea JI; Moutardier V; Gasmi M; Ouaissi M; Turrini O; Delpero JR; Dusetti N; Iovanna J
    Oncoscience; 2015; 2(6):572-5. PubMed ID: 26244163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of cancer stem cell markers in pancreatic intraepithelial neoplasias and pancreatic ductal adenocarcinomas.
    Kure S; Matsuda Y; Hagio M; Ueda J; Naito Z; Ishiwata T
    Int J Oncol; 2012 Oct; 41(4):1314-24. PubMed ID: 22824809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Lamichhane P; Messaggio F; Shi C; Dai X; Rai P; Chen X; VanSaun MN; Merchant NB
    Cancer Res; 2018 Nov; 78(21):6235-6246. PubMed ID: 30154150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRM270 Inhibits the Proliferation of CD44 Positive Pancreatic Ductal Adenocarcinoma Cells via Downregulation of Sonic Hedgehog Signaling.
    Huynh DL; Koh H; Chandimali N; Zhang JJ; Kim N; Kang TY; Ghosh M; Gera M; Park YH; Kwon T; Jeong DK
    Evid Based Complement Alternat Med; 2019; 2019():8620469. PubMed ID: 31049070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoresistance Transmission
    Li X; Li K; Li M; Lin X; Mei Y; Huang X; Yang H
    Front Oncol; 2022; 12():844648. PubMed ID: 35223528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD44 Predicts Early Recurrence in Pancreatic Cancer Patients Undergoing Radical Surgery.
    Hsu CP; Lee LY; Hsu JT; Hsu YP; Wu YT; Wang SY; Yeh CN; Chen TC; Hwang TL
    In Vivo; 2018; 32(6):1533-1540. PubMed ID: 30348713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-410-3p attenuates gemcitabine resistance in pancreatic ductal adenocarcinoma by inhibiting HMGB1-mediated autophagy.
    Xiong J; Wang D; Wei A; Ke N; Wang Y; Tang J; He S; Hu W; Liu X
    Oncotarget; 2017 Dec; 8(64):107500-107512. PubMed ID: 29296182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perspectives in the treatment of pancreatic adenocarcinoma.
    Cid-Arregui A; Juarez V
    World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-based targeting of alternatively spliced tissue factor: a new approach to impede the primary growth and spread of pancreatic ductal adenocarcinoma.
    Unruh D; Ünlü B; Lewis CS; Qi X; Chu Z; Sturm R; Keil R; Ahmad SA; Sovershaev T; Adam M; Van Dreden P; Woodhams BJ; Ramchandani D; Weber GF; Rak JW; Wolberg AS; Mackman N; Versteeg HH; Bogdanov VY
    Oncotarget; 2016 May; 7(18):25264-75. PubMed ID: 26967388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer.
    Adamska A; Domenichini A; Capone E; Damiani V; Akkaya BG; Linton KJ; Di Sebastiano P; Chen X; Keeton AB; Ramirez-Alcantara V; Maxuitenko Y; Piazza GA; De Laurenzi V; Sala G; Falasca M
    J Exp Clin Cancer Res; 2019 Aug; 38(1):312. PubMed ID: 31378204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ezrin Promotes Stem Cell Properties in Pancreatic Ductal Adenocarcinoma.
    Penchev VR; Chang YT; Begum A; Ewachiw T; Gocke C; Li J; McMillan RH; Wang Q; Anders R; Marchionni L; Maitra A; Uren A; Rasheed Z; Matsui W
    Mol Cancer Res; 2019 Apr; 17(4):929-936. PubMed ID: 30655325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis.
    Durko L; Wlodarski W; Stasikowska-Kanicka O; Wagrowska-Danilewicz M; Danilewicz M; Hogendorf P; Strzelczyk J; Malecka-Panas E
    Dis Markers; 2017; 2017():3276806. PubMed ID: 28659655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
    Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
    BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD44 SNPrs187115: A Novel Biomarker Signature that Predicts Survival in Resectable Pancreatic Ductal Adenocarcinoma.
    Stracquadanio G; Vrugt B; Flury R; Schraml P; Würl P; Müller TH; Knippschild U; Henne-Bruns D; Breitenstein S; Clavien PA; Graf R; Bond GL; Grochola LF
    Clin Cancer Res; 2016 Dec; 22(24):6069-6077. PubMed ID: 27283965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma.
    Al Haddad AH; Adrian TE
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1499-515. PubMed ID: 25078674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PDE3 inhibitor and EGCG combination treatment suppress cancer stem cell properties in pancreatic ductal adenocarcinoma.
    Kumazoe M; Takai M; Hiroi S; Takeuchi C; Yamanouchi M; Nojiri T; Onda H; Bae J; Huang Y; Takamatsu K; Yamashita S; Yamada S; Kangawa K; Takahashi T; Tanaka H; Tachibana H
    Sci Rep; 2017 May; 7(1):1917. PubMed ID: 28507327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-Expression of Cancer Stem Cell Markers Corresponds to a Pro-Tumorigenic Expression Profile in Pancreatic Adenocarcinoma.
    Skoda J; Hermanova M; Loja T; Nemec P; Neradil J; Karasek P; Veselska R
    PLoS One; 2016; 11(7):e0159255. PubMed ID: 27414409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreatic cancer stem cell proliferation is strongly inhibited by diethyldithiocarbamate-copper complex loaded into hyaluronic acid decorated liposomes.
    Marengo A; Forciniti S; Dando I; Dalla Pozza E; Stella B; Tsapis N; Yagoubi N; Fanelli G; Fattal E; Heeschen C; Palmieri M; Arpicco S
    Biochim Biophys Acta Gen Subj; 2019 Jan; 1863(1):61-72. PubMed ID: 30267751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Evaluation of Vimentin Expression in Correlation with Ki67 and CD44 in Surgically Resected Pancreatic Ductal Adenocarcinoma.
    Myoteri D; Dellaportas D; Lykoudis PM; Apostolopoulos A; Marinis A; Zizi-Sermpetzoglou A
    Gastroenterol Res Pract; 2017; 2017():9207616. PubMed ID: 28421110
    [No Abstract]   [Full Text] [Related]  

  • 20. KLF4-Mediated Suppression of CD44 Signaling Negatively Impacts Pancreatic Cancer Stemness and Metastasis.
    Yan Y; Li Z; Kong X; Jia Z; Zuo X; Gagea M; Huang S; Wei D; Xie K
    Cancer Res; 2016 Apr; 76(8):2419-31. PubMed ID: 26880805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.